M&A · Healthcare · Services-Medical Laboratories
Reaction Biology to acquire Vyant Bio, Inc.
Announced Nov 3, 2022 · Closed May 4, 2023
Deal value$6MEV $6M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationNot disclosed
Transaction
- Acquirer
- Reaction Biology
- Target
- Vyant Bio, Inc. (VYNT)
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- $6M
- Status
- Closed May 4, 2023
Deal protections
Not yet read from the merger agreement.
Advisors
- To the acquirer
- Not disclosed
- To the target
- Lake Street
Sector context · Healthcare
- Comparable deals
- 70 in the prior 24 months
- Premium
- Sector median 47.0%
- EV / Adj. EBITDA
- Sector median 18.4x
- Break fee
- Sector median 3.4%
Timeline
- AnnouncedNov 3, 2022
- ClosedMay 4, 2023